Microbiotica has dosed the first subject in the Phase Ib MELODY-1 clinical trial of MB097, a precision microbiome co-therapy ...

Wellcome Sanger Institute spin-out Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision ...

Being Tested in Combination with MSD’s anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab) Cambridge, UK – 10 October 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral ...

Microbiotica was founded in 2016 in Cambridge, UK, to translate pioneering research from the Wellcome Sanger Institute into novel, microbiome-based precision medicines. It has developed the ...

Microbiotica is a spin-out from the not-for-profit Wellcome Trust Sanger Institute (pictured) which specialises in genome sequencing and has been researching the microbiome since 2010. The UK ...

CAMBRIDGE, United Kingdom, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Microbiotica, a biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products ...

The Barcelona-based startup Sequentia Biotech has raised €10 million ($11 million) in a Series A round to finance the ...

Yet, there remain technical barriers to predictable translation in this emerging field. Microbiotica is addressing the barriers and helping drive a new era of rigorous, data-driven microbiome R&D.

Tulisokibart is a tumor necrosis factor (TNF)-like cytokine 1A (TL1A) monoclonal antibody with a different mechanism of ...

A new multimillion-pound research programme, involving scientists from The Institute of Cancer Research, London, is aiming to ...